SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Christopher D.�M. Fletcher et al.|Journal of Clinical Oncology|2004Cited by 103
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Jayesh Desai et al.|Journal of Clinical Oncology|2004Cited by 46